Search

Your search keyword '"Gratecos, N."' showing total 229 results
Start Over Author "Gratecos, N."
229 results on '"Gratecos, N."'

3. Double Reduced-Intensity Allogeneic Hematopoietic Stem Cell Transplantation: A Retrospective Study from the SFGM-TC

Author

Bay, J.O., Cabrespine, A., Faucher, C., Tabrizi, R., Bordigoni, P., Berceanu, A., Coiteux, V., Renaud, M., Mialou, V., Robin, M., Kuentz, M., Chevallier, P., Dhédin, N., Huynh, A., Garban, F., Witz, F., Buzyn, A., De Revel, T., Galambrun, C., Deconinck, E., Contentin, N., François, S., Gratecos, N., Blaise, D., and Michallet, M.

Published
2012
Full Text
View/download PDF

4. Quinine Improves Results of Intensive Chemotherapy (IC) in Myelodysplastic Syndromes (MDS) Expressing P-Glycoprotein (PGP) : Updated Results of a Randomized Study

Author

Wattel, E., Solary, E., Hecquet, B., Caillot, D., Ifrah, N., Brion, A., Milpied, N., Janvier, M., Guerci, A., Rochant, H., Cordonnier, C., Dreyfus, F., Veil, A., Hoang-Ngoc, L., Stoppa, A. M., Gratecos, N., Sadoun, A., Tilly, H., Brice, P., Lioure, B., Desablens, B., Pignon, B., Abgrall, J. P., Leporrier, M., Dupriez, B., Guyotat, D., Lepelley, P., Fenaux, P., Kaspers, G. J. L., editor, Pieters, R., editor, and Veerman, A. J. P., editor

Published
1999
Full Text
View/download PDF

5. Early Allogeneic Transplantation Favorably Influences the Outcome of Adult Patients Suffering from Acute Myeloid Leukemia

Author

Jourdan, E., Maraninchi, D., Reiffers, J., Gluckman, E., Rio, B., Jouet, J. P., Michallet, M., Molina, L., Archimbaud, E., Harousseau, J. L., Ifrah, N., Attal, M., Guilhot, F., Kuentz, M., Guyotat, D., Pico, J. L., Dauriac, C., Legros, M., Dreyfus, F., Bordigoni, P., Leblond, V., Gratecos, N., Varet, B., Auzanneau, C., Tilly, H., Vilmer, E., Bardou, V. J., Blaise, D., Hiddemann, W., editor, Büchner, T., editor, Wörmann, B., editor, Ritter, J., editor, Creutzig, U., editor, Keating, M., editor, and Plunkett, W., editor

Published
1998
Full Text
View/download PDF

6. Comparison of Chemotherapy and Autologous and Allogeneic Transplantation as Postinduction Regimen in Adult Acute Lymphoblastic Leukemia: a Preliminary Multicentric Study

Author

Fiere, D., Broustet, A., Leblond, V., Maraninchi, D., Castaigne, S., Flesch, M., Varet, B., Vernant, J. P., Milpied, N., Troussard, X., Pignon, B., Archimbaud, E., Dufour, P., Pris, J., Pico, J. L., Michallet, M., Gratecos, N., Briere, J., Travade, H., Guilhot, P., Desablens, B., Guy, H., Tilly, H., Jaubert, J., Witz, F., Büchner, T., editor, Schellong, G., editor, Hiddemann, W., editor, and Ritter, J., editor

Published
1990
Full Text
View/download PDF

7. Intensive Therapy of Myelodysplastic Syndromes and Secondary Leukemias: Preliminary Findings of the French Experience

Author

Wattel, E., Solary, E., Caillot, D., Ifrah, N., Brion, A., Milpied, N., Janvier, M., Guerci, A., Rochant, H., Cordonnier, C., Dreyfus, F., Veil, A., Stoppa, A. M., Gratecos, N., Sadoun, A., Tilly, H., Brice, P., Lioure, B., Desablens, B., Pignon, B., Abgrall, J. P., Leporrier, M., Dupriez, B., Guyotat, D., Merlat, A., Fenaux, P., Büchner, T., editor, Schellong, G., editor, Ritter, J., editor, Creutzig, U., editor, Hiddemann, W., editor, and Wörmann, B., editor

Published
1997
Full Text
View/download PDF

8. Allogeneic stem cell transplantation improves the outcome of adults with t(1;19)/E2A-PBX1 and t(4;11)/MLL-AF4 positive B-cell acute lymphoblastic leukemia: results of the prospective multicenter LALA-94 study

Author

Vey, N, Thomas, X, Picard, C, Kovascovicz, T, Charin, C, Cayuela, J M, Dombret, H, Dastugue, N, Huguet, F, Bastard, C, Stamatoulas, A, Giollant, M, Tournilhac, O, Macintyre, E, Buzyn, A, Bories, D, Kuentz, M, Dreyfus, F, Delannoy, A, Raynaud, S, Gratecos, N, Bordessoule, D, de Botton, S, Preudhomme, C, Reman, O, Troussard, X, Pigneux, A, Bilhou, C, Vernant, J P, Boucheix, C, and Gabert, J

Published
2006
Full Text
View/download PDF

11. Long-term outcome after allogeneic hematopoietic stem cell transplantation for advanced stage acute myeloblastic leukemia: a retrospective study of 379 patients reported to the Société Française de Greffe de Moelle (SFGM)

Author

Michallet, M, Thomas, X, Vernant, JP, Kuentz, M, Socié, G, Espérou-Bourdeau, H, Milpied, N, Blaise, D, Rio, B, Reiffers, J, Jouet, JP, Cahn, JY, Bourhis, JH, Lioure, B, Leporrier, M, Sotto, JJ, Souillet, G, Sutton, L, Bordigoni, P, Dreyfus, F, Tilly, H, Gratecos, N, Attal, M, Leprise, PY, Déméocq, F, Michel, G, Buzyn, A, Delmas-Marsalet, B, Bernaudin, F, Ifrah, N, Sadoun, A, Guyotat, D, Cavazzana-Cavo, M, Caillot, D, De Revel, T, Vannier, JP, Baruchel, A, Fegueux, N, Tanguy, ML, Thiébaut, A, Belhabri, A, and Archimbaud, E

Published
2000
Full Text
View/download PDF

12. Treatment of relapsing acute promyelocytic leukemia by all-trans retinoic acid therapy followed by timed sequential chemotherapy and stem cell transplantation

Author

Thomas, X, Dombret, H, Cordonnier, C, Pigneux, A, Gardin, C, Guerci, A, Vekhoff, A, Sadoun, A, Stamatoullas, A, Fegueux, N, Maloisel, F, Cahn, JY, Reman, O, Gratecos, N, Berthou, C, Huguet, F, Kotoucek, P, Travade, P, Buzyn, A, de Revel, T, Vilque, JP, Naccache, P, Chomienne, C, Degos, L, and Fenaux, P

Published
2000
Full Text
View/download PDF

16. Early allogeneic transplantation favorably influences the outcome of adult patients suffering from acute myeloid leukemia

Author

Jourdan, E, Maraninchi, D, Reiffers, J, Gluckman, E, Rio, B, Jouet, JP, Michallet, M, Molina, L, Archimbaud, E, Harousseau, JL, Ifrah, N, Attal, M, Guilhot, F, Kuentz, M, Guyotat, D, Pico, JL, Dauriac, C, Legros, M, Dreyfus, F, Bordigoni, P, Leblond, V, Gratecos, N, Varet, B, Auzanneau, C, Tilly, H, Vilmer, E, Bardou, VJ, and Blaise, D

Published
1997
Full Text
View/download PDF

21. Therapy-Related Acute Promyelocytic Leukemia

Author

Beaumont, M., Sanz, M., Carli, P.M., Maloisel, F., Thomas, X., Detourmignies, L., Guerci, A., Gratecos, N., Rayon, C., Miguel, J. San, Odriozola, J., Cahn, J.Y., Huguet, F., Vekhof, A., Stamatoulas, A., Dombret, H., Capote, F., Esteve, J., Stoppa, A.M., and Fenaux, P.

Published
2003

23. Quinine Improves Results of Intensive Chemotherapy (IC) in Myelodysplastic Syndromes (MDS) Expressing P-Glycoprotein (PGP)

Author

Wattel, E., primary, Solary, E., additional, Hecquet, B., additional, Caillot, D., additional, Ifrah, N., additional, Brion, A., additional, Milpied, N., additional, Janvier, M., additional, Guerci, A., additional, Rochant, H., additional, Cordonnier, C., additional, Dreyfus, F., additional, Veil, A., additional, Hoang-Ngoc, L., additional, Stoppa, A. M., additional, Gratecos, N., additional, Sadoun, A., additional, Tilly, H., additional, Brice, P., additional, Lioure, B., additional, Desablens, B., additional, Pignon, B., additional, Abgrall, J. P., additional, Leporrier, M., additional, Dupriez, B., additional, Guyotat, D., additional, Lepelley, P., additional, and Fenaux, P., additional

Published
1999
Full Text
View/download PDF

26. Intensive Therapy of Myelodysplastic Syndromes and Secondary Leukemias: Preliminary Findings of the French Experience

Author

Wattel, E., primary, Solary, E., additional, Caillot, D., additional, Ifrah, N., additional, Brion, A., additional, Milpied, N., additional, Janvier, M., additional, Guerci, A., additional, Rochant, H., additional, Cordonnier, C., additional, Dreyfus, F., additional, Veil, A., additional, Stoppa, A. M., additional, Gratecos, N., additional, Sadoun, A., additional, Tilly, H., additional, Brice, P., additional, Lioure, B., additional, Desablens, B., additional, Pignon, B., additional, Abgrall, J. P., additional, Leporrier, M., additional, Dupriez, B., additional, Guyotat, D., additional, Merlat, A., additional, and Fenaux, P., additional

Published
1997
Full Text
View/download PDF

27. Allogeneic Bone Marrow Transplantation for Therapy-Related Myelodysplastic Syndrome and Acute Myeloid Leukemia: A Long-Term Study of 70 Patients—Report of the French Society of Bone Marrow Transplantation

Author

Yakoub-Agha, I., de La Salmonière, P., Ribaud, P., Sutton, L., Wattel, E., Kuentz, M., Jouet, J. P., Marit, G., Milpied, N., Deconinck, E., Gratecos, N., Leporrier, M., Chabbert, I., Caillot, D., Damaj, G., Dauriac, C., Dreyfus, F., François, S., Molina, L., Tanguy, M. L., Chevret, S., and Gluckman, E.

Published
2000

28. Quinine improves the results of intensive chemotherapy in myelodysplastic syndromes expressing P glycoprotein: results of a randomized study

Author

Wattel, E., Solary, E., Hecquet, B., Caillot, D., Ifrah, N., Brion, A., Mahe, B., Milpied, N., Janvier, M., Guerci, A., Rochant, H., Cordonnier, C., Dreyfus, F., Buzyn, A., Hoang-Ngoc, L., Stoppa, A. M., Gratecos, N., Sadoun, A., Stamatoulas, A., Tilly, H., Brice, P., Maloisel, F., Lioure, B., Desablens, B., Pignon, B., Abgrall, J. P., Leporrier, M., Dupriez, B., Guyotat, D., Lepelley, P., and Fenaux, P.

Published
1998

29. QUININE IMPROVES RESULTS OF INTENSIVE CHEMOTHERAPY IN MYELODYSPLASTIC SYNDROMES (MDS) EXPRESSING P GLYCOPROTEIN (PGP): UPDATED RESULTS OF A RANDOMIZED STUDY

Author

Wattel, E., Solary, E., Hecquet, B., Caillot, D., Ifrah, N., Brion, A., Milpied, N., Janvier, M., Guerci, A., Rochant, H., Cordonnier, C., Dreyfus, F., Veil, A., Hoang-Ngoc, L., Stoppa, A. M., Gratecos, N., Sadoun, A., Tilly, H., Brice, P., Lioure, B., Desablens, B., Pignon, B., Abgrall, J. P., Leporrier, M., Dupriez, B., Guyotat, D., Lepelley, P., and Fenaux, P.

Published
1998

31. Comparison of Chemotherapy and Autologous and Allogeneic Transplantation as Postinduction Regimen in Adult Acute Lymphoblastic Leukemia: a Preliminary Multicentric Study

Author

Fiere, D., primary, Broustet, A., additional, Leblond, V., additional, Maraninchi, D., additional, Castaigne, S., additional, Flesch, M., additional, Varet, B., additional, Vernant, J. P., additional, Milpied, N., additional, Troussard, X., additional, Pignon, B., additional, Archimbaud, E., additional, Dufour, P., additional, Pris, J., additional, Pico, J. L., additional, Michallet, M., additional, Gratecos, N., additional, Briere, J., additional, Travade, H., additional, Guilhot, P., additional, Desablens, B., additional, Guy, H., additional, Tilly, H., additional, Jaubert, J., additional, and Witz, F., additional

Published
1990
Full Text
View/download PDF

34. Fluorescence in situ hybridization analysis of t(3; 12)(q26; p13): a recurring chromosomal abnormality involving the TEL gene (ETV6) in myelodysplastic syndromes

Author

J. Grosgeorge, M Baens, Gratecos N, P Marynen, C. D. L. Reid, B. Taillan, Sophie Raynaud, K. Rodgers, Martin J. S. Dyer, M. Dainton, Noel Ayraud, and J. G. Fuzibet

Subjects
medicine.medical_specialty, medicine.diagnostic_test, Myelodysplastic syndromes, Immunology, Cytogenetics, Myeloid leukemia, Cell Biology, Hematology, Biology, medicine.disease, Biochemistry, Molecular biology, Myelogenous, ETV6, hemic and lymphatic diseases, medicine, Chromosome abnormality, Fluorescence in situ hybridization, Chronic myelogenous leukemia
Abstract

We have identified a new recurrent reciprocal translocation between chromosome 3 and 12 with breakpoints at bands 3q26 and 12p13, t(3;12)(q26;p13) in the malignant cells from five patients with acute transformation of myelodysplastic syndrome or blast crisis of chronic myelogenous leukemia. t(3;12)(q26;p13) appears as a rare but nonrandom event present in various myeloid leukemia subtypes, which is frequently associated with dysplasia of megakaryocytes, multilineage involvement, short duration of any blastic phase, and a very poor prognosis. Here, we report the molecular cytogenetic analysis of the t(3;12). Fluorescence in situ hybridization results indicate that the 3q26 breakpoints are quite heterogeneous and occur 5′ of MDS1, 3′ of EVI1, or between MDS1 and EVI1. Our results are very similar to those observed in other 3q26 rearrangements in which breakpoints were shown to occur over considerable distances 5′ and 3′ of EVI1. Fluorescence in situ hybridization investigations proved that, in three myelodysplastic syndrome cases with t(3;12)(q26;p13), the 12p 13 breakpoint occurred within the TEL gene.

Published
1996
Full Text
View/download PDF

35. Long-term follow-up of autologous stem cell transplantation after intensive chemotherapy in patients with myelodysplastic syndrome or secondary acute myeloid leukemia

Author

Ducastelle, S., Adès, L., Gardin, C., Dombret, H., Prébet, T., Eric DECONINCK, Rio, B., Thomas, X., Debotton, S., Guerci, A., Gratecos, N., Stamatoullas, A., Fegueux, N., Dreyfus, F., Fenaux, P., Wattel, E., Service d'hématologie [Hôpital Edouard Herriot - HCL], Hôpital Edouard Herriot [CHU - HCL], Hospices Civils de Lyon (HCL)-Hospices Civils de Lyon (HCL), Service d'hématologie biologique, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Groupe Hospitalier Saint Louis - Lariboisière - Fernand Widal [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Service d'hématologie clinique [Avicenne], Université Paris 13 (UP13)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Avicenne [AP-HP], Service d'hématologie, Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon), Interactions hôte-greffon-tumeur, ingénierie cellulaire et génique - UFC (UMR INSERM 1098) (RIGHT), Institut National de la Santé et de la Recherche Médicale (INSERM)-Etablissement français du sang [Bourgogne-Franche-Comté] (EFS [Bourgogne-Franche-Comté])-Université de Franche-Comté (UFC), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôtel-Dieu, Institut Mondor de Recherche Biomédicale (IMRB), Institut National de la Santé et de la Recherche Médicale (INSERM)-IFR10-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), Service d'Hématologie [CHRU Nancy], Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy), Service Hématologie, Centre Hospitalier Universitaire de Nice (CHU Nice), Service d'hématologie et oncologie médicale, Université Montpellier 1 (UM1)-Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Hôpital Lapeyronie-Université de Montpellier (UM), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Cochin [AP-HP], Virologie et pathogenèse virale (VPV), Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Centre National de la Recherche Scientifique (CNRS), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris 13 (UP13)-Hôpital Avicenne [AP-HP], Centre de Lutte Contre le Cancer Henri Becquerel Normandie Rouen (CLCC Henri Becquerel), Hôpital Lapeyronie-Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Université Montpellier 1 (UM1)-Université de Montpellier (UM), Centre National de la Recherche Scientifique (CNRS)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon, and Saas, Philippe

Subjects
[SDV.MHEP.HEM] Life Sciences [q-bio]/Human health and pathology/Hematology, Adult, Male, autologous stem cell transplantation, Adolescent, MESH: Survival Rate, Antineoplastic Agents, Transplantation, Autologous, Time, MESH: Transplantation, Homologous, Humans, Transplantation, Homologous, Aged, MESH: Adolescent, MESH: Aged, MESH: Humans, MESH: Middle Aged, MESH: Time, intensive chemotherapy, MESH: Adult, [SDV.MHEP.HEM]Life Sciences [q-bio]/Human health and pathology/Hematology, MESH: Follow-Up Studies, Middle Aged, MESH: Transplantation, Autologous, MESH: Male, myelodysplastic syndrome, Survival Rate, Leukemia, Myeloid, Acute, Myelodysplastic Syndromes, MESH: Antineoplastic Agents, Female, MESH: Stem Cell Transplantation, MESH: Leukemia, Myeloid, Acute, MESH: Myelodysplastic Syndromes, MESH: Female, Follow-Up Studies, Stem Cell Transplantation
Abstract

International audience; We report on the outcomes of 53 patients with myelodysplastic syndromes (MDS) or acute myeloid leukemia secondary to MDS, autografted in first complete remission. Five (9.4%) died from the procedure whereas hematological reconstitution occurred in all the remaining patients. Forty patients (75%) relapsed, with 87.5% of the relapses occurring within 2 years of the autologous transplant. With a median follow-up of 6.2 years, the median actuarial disease-free survival and overall survival were 8 and 17 months after autograft, respectively. Karyotype was the only prognostic factor for disease-free and overall survival. The eight survivors (15%), including two patients with unfavorable or intermediate karyotype, remained in first complete remission 50+ to 119+ months after transplantation and are probably cured.

Published
2006

36. Marrow versus peripheral blood for geno-identical allogeneic stem cell transplantation in acute myelocytic leukemia: Influence of dose and stem cell source shows better outcome with rich marrow

Author

Gorin N.C., Labopin M., Rocha V., Arcese W., Beksac M., Gluckman E., Ringden O., Ruutu T., Reiffers J., Bandini G., Falda M., Zikos P., Willemze R., Frassoni F., Abecasis M., Abráhamová J., Afanassiev B.V., Aglietta M., Alabdulaaly A., Aleinikova O., Paolo Alessandrino E., Al Shemmari S.H., Amadori D., Amadori S., Amos T., Andolina M., Andreesen R., Angelucci E., Anhuf J., Arnold R., Arpaci F., Attal M., Azevedo W., Azim H.A., Baccarani M., Bacigalupo A., Barbui T., Bargetzi M., Barnard D.L., Bartsch H.H., Baruchel A., Battista C., Bay J.-O., Bayik M., Bazarbachi A., Beguin Y., López J.L.B., Benedek I., Benedetti F., Bengala C., Berrebi A., Besalduch J., Biesma D., Biron P., Björkholm M., Blaise D., Blesing N.E., Boasson M., Bobev D., Boccadoro M., Bolaman Z., Boogaerts M.A., Bordessoule D., Bosi A., Aida B.S., Bourhis J.H., Bourikas G., Bowen D.T., Bregni M., Bries G., Brinch L., Brittain D., Bron D., Brune M., Bullorsky E.O., Bunjes D., Burdach S., Burnett A.K., Buzyn A., Caballero D., Cagirgan S., Cahn J.-Y., Canepa C.O., Cao A., Carella A.M., Carrera F.D., Carret A.-S., Cascinu S., Castel V., Caswell M., Cavanna L., Cetto G.L., Chapuis B., Chasty R., Chen Y.-C., Chisesi T., Chopra R., Chybicka A., Clark R.E., Colombat P., Colovic M.D., Constenla-Figueiras M., Contreras M., Contu L., Cordonnier C., Cornelissen J.J., Cornish J., Coser P., Costa N., Coze C., Craddock C., Crown J., Culligan D.J., Danova M., Darbyshire P.J., Davies J.M., de Bock R., de Pablos Gallego J.M., De Prijck B., de Revel T., De Rossi G., De Souza C.A., Deb G., Degos L., Demuynck H., Dervenoulas I., Di Bartolomeo P., Di Renzo N., Diaz M.A., Diehl V., Diez-Martin J.L., Dincer S., Giorgio D., Dmoszynska A., Doelken G., Peter P.D., Dulley F., Easow J., Ebell W., Efremidis A., Ehninger G., Eichler H., Eimermacher H., Enno A., Errazquin L., Aguado J.E., Everaus H., Fagioli F., Fanin R., Fassas A., Fasth A., Faulkner L.B., Fauser A.A., Feldman L., Feremans W., Ferhanoglu B., Fernández M.N., Fernández-Ranada J.M., Ferrant A., Ferrara F., Finke J., Fischer A., Fischer J., Fitzsimons T., Floristan F., Forjaz de Lacerda J.M.F., Fossati-Bellani F., Fosser V., Franklin I., Freund M., Frickhofen N., Gabbas A., Gadner H., Gallamini A., Galvin M.C., López J.G., García-Conde J., Gaska T., Gastl G., Gedikoglu G., Ghavamzadeh A., Gianni A., Gibson B.E., Gil J.L., Gilleece M.H., Gisselbrecht C., Glass B., Gmür J., Göbel U., Goldman J.M., Goldstone A.H., San Miguel J.D.G., González-López M.-A., Grafakos S., Gramatzki M., Grañena A., Gratecos N., Gratwohl A., Greinix H.T., Gugliotta L., Guilhot F., Guimaraes J.E., Gülbas Z., Gulyuz O., Gurman G., Gutierrez M.M., Haas R., Hamladji R.-M., Hamon M.D., Hansen N.E., Harhalakis N., Harousseau J.L., Hartenstein R., Hartmann C.O., Hausmaninger H., Haznedar R., Heit W., Hellmann A., Herrmann R.P., Hertenstein B., Hess U., Hinterberger W., Ho A.D., Hoelzer D., Holowiecki J., Horst H.-A., Hossfeld D.K., Huebsch L., Hunter A.E., Iacopino P., Iannitto E., Indrák K., Iriondo A., Izzi T., Jackson G.L., Jacobs P., Jacobsen N., Janvier M., Jebavy L., Joensuu H., Joerg S., Jones F.G.C., Jouet J.P., Joyner M.V., Juliusson G., Jürgens H., Kalayoglu-Besisik S., Kalman N., Kalmanti M., Kansoy S., Kansu E., Kanz L., Karianakis G., Kernéis Y., Khalifeh O., Khomenko V., Kienast J., Killick S., Kirchner H.H., Klingebiel T., Knauf W., Koenigsmann M., Koistinen P., Koivunen E., Kolb H.-J., Kolbe K., Koller E., Komarnicki M., Koscielniak E., Kovacsovics T., Kowalczyk J.R., Koza V., Kozak T., Kugler J., Kuliczkowski K., Kvaloy S., Labar B., Laciura P., Palacios J.J.L., Lakota J., Lambertenghi D.G., Lange A., Lanza F., Isasti R.L., Lauria F., Le Moine F., Leblond V., Lelli G., Lenhoff S., Leon L.A., Leoncini-Franscini L., Leone G., Leoni P., Levis A., Leyvraz S., Liberati M., Link H., Linkesch W., Liso V., Lisukov I.A., Littlewood T., Ljungman P., Locatelli F., Losonczy H., Lotz J.-P., Ludwig H., Lukac J., Lutz D., Macchia P., Madrigal A., Maiolino A., Majolino I., Eloy-García J.M., Malesevic M., Mandelli F., Marc A., Marcus R., Marianska B., Markuljak I., Marsh J.C.W., Martelli M.F., Marti Tutusaus J.M., Martin S., Martin M., Martinelli G., Martínez-Rubio A.M., Martoni A., Maschan A., Maschmeyer G., Masszi T., Mazza P., McCann S., Meier C.R., Messina C., Mettivier V., Metzner B., Michallet M., Michieli M., Michon J., Milligan D.W., Milone J.H., Giuseppe G.M., Minigo H., Mistrik M., Moicean A.D., Monfardini S., Montserrat E., Moraleda Jimenez J.M., Morales-Lazaro A., Morandi S., Morra E., Mufti G.J., Musso M., Nagler A., Nalli G., Naparstek E., Narni F., Nenadov-Beck M., Neubauer A., Newland A.C., Niederwieser D., Niethammer D., Noens L.A., Nousiainen T., Novik A., Novitzky N., Occhini D., Odriozolas J., Ojanguren J.M., O’meara A., Onat H., Orchard K., Ortega J.J., Osieka R., Ossenkoppele G.J., Othman B., Ovali E., Ozcebe O.I., Ozerkan K., Ozturk A., Papatryfonos A., Parker J.E., Pastore M., Patrone F., Patton N., Pejin D., Peñarrubia M.J., Equiza E.P., Peschel C., Pession A., Pigaditou A., Pignon B., Pihkala U., Pimentel P., Pitini V., Podoltseva E., Pogliani E.M., Anna A.P., Porta F., Potter M., Powles R., Prentice G.H., Pretnar J., Ptushkin V., Quarta G., Reiter A., Remes K., Reykdal S., Santasusana J.M.R., Rifón J., Rio B., Rizzoli V., Robak T., Robinson A.J., Rodeghiero F., Rodríguez Fernández J.M., Rombos Y., Romeril K.R., Rosenmayr A., Rossi J.F., Rosti G., Rotoli B., Rowe J.M., Russell N.H., Ryzhak O., Rzepecki P., Saglio G., Salwender H., Samonigg H., Santoro A., Sanz M.A., Sayer H.G., Scanni A., Schaafsma M.R., Schaefer U.W., Schanz U., Schattenberg A., Schey S.A.M., Schlimok G., Schmoll H.-J., Schots R., Schouten H., Schwarer A.P., Schwerdtfeger R., Scimè R., Segel E., Seger R., Selleslag D., Serban M., Shamaa S., Shaw P.J., Siegert W., Siena S., Sierra J., Simonsson B., Singer C.R.J., Sirchia G., Skotnicki A.B., Slavin S., Snowden J., Sotto J.J., Tanyeli A., Tedeschi L., Tidefelt U., Tissot J.-D., Tobler A., Tomas J.F., Torres J.P., Torres G.A., Touraine J.-L., Trneny M., Uderzo C., Unal E., Unal A., Undar L., Urban C., Van den Berg H., van Marwijk K.M., Vellenga E., Venturini M., Verdonck L.F., Veys P., Vilardell J., Vinante O., Visani G., Vitek A., Vivancos P., Volpe E., Vora A., Vorlicek J., Vowels M., Vujic D., Wachowiak J., Wagner T., Wahlin A., Walewski J., Wandt H., Weissinger F., Wijermans P.W., Wiktor-Jedrzejczak W., Will A.M., Woell E., Wörmann B., Yaniv I., Yesilipek M.A., Yilmaz U., Yong A., Zachée P., Zambelli A., Zander A.R., Zintl F., Zoumbos N.C., Çukurova Üniversitesi, Maltepe Üniversitesi, and Ege Üniversitesi

Subjects
Myeloid, Male, Pathology, Time Factors, Graft vs Host Disease, Biochemistry, Gastroenterology, Blood cell, Bone Marrow, Child, Bone Marrow Transplantation, Leukemia, Remission Induction, Hematology, Middle Aged, Prognosis, Leukemia, Myeloid, Acute, ComputingMilieux_MANAGEMENTOFCOMPUTINGANDINFORMATIONSYSTEMS, medicine.anatomical_structure, Treatment Outcome, Child, Preschool, Female, Stem cell, InformationSystems_MISCELLANEOUS, Homologous, Adult, medicine.medical_specialty, Adolescent, Immunology, Acute, Disease-Free Survival, Internal medicine, medicine, Transplantation, Homologous, Humans, Preschool, Aged, Transplantation, business.industry, ComputerSystemsOrganization_COMPUTER-COMMUNICATIONNETWORKS, Cell Biology, medicine.disease, Peripheral blood, Histocompatibility, Multivariate Analysis, Stem Cell Transplantation, ComputingMethodologies_PATTERNRECOGNITION, Myelocytic leukemia, Bone marrow, business, Settore MED/15 - Malattie del Sangue
Abstract

PubMed ID: 12829583, Several studies have compared bone marrow (BM) and peripheral blood (PB) as stem cell sources in patients receiving allografts, but the cell doses infused have not been considered, especially for BM. Using the ALWP/EBMT registry, we retrospectively studied 881 adult patients with acute myelocytic leukemia (AML), who received a non-T-depleted allogeneic BM (n = 515) or mobilized PB (n = 366) standard transplant, in first remission (CR1), from an HLA-identical sibling, over a 5-year period from January 1994. The BM cell dose ranged from 0.17 to 29 × 10 8 /kg with a median of 2.7 × 10 8 /kg. The PB cell dose ranged from 0.02 to 77 × 10 8 /kg with a median of 9.3 × 10 8 /kg. The median dose for patients receiving BM (2.7 × 10 8 /kg) gave the greatest discrimination. In multivariate analyses, high-dose BM compared to PB was associated with lower transplant-related mortality (RR = 0.61; 95% CI, 0.39-0.98; P = .04), better leukemia-free survival (RR = 0.65; 95% CI, 0.46-0.91; P = .013), and better overall survival (RR = 0.64; 95% CI, 0.44-0. 92; P = .016). The present study in patients with AML receiving allografts in first remission indicates a better outcome with BM as compared to PB, when the dose of BM infused is rich. © 2003 by The American Society of Hematology.

Published
2003

37. Marrow versus peripheral blood for geno-identical allogeneic stem cell transplantation in acute myelocytic leukemia: Influence of dose and stem cell source shows better outcome with rich marrow

Author

Gorin, N.C. Labopin, M. Rocha, V. Arcese, W. Beksac, M. Gluckman, E. Ringden, O. Ruutu, T. Reiffers, J. Bandini, G. Falda, M. Zikos, P. Willemze, R. Frassoni, F. Abecasis, M. Abráhamová, J. Afanassiev, B.V. Aglietta, M. Alabdulaaly, A. Aleinikova, O. Paolo Alessandrino, E. Al Shemmari, S.H. Amadori, D. Amadori, S. Amos, T. Andolina, M. Andreesen, R. Angelucci, E. Anhuf, J. Arnold, R. Arpaci, F. Attal, M. Azevedo, W. Azim, H.A. Baccarani, M. Bacigalupo, A. Barbui, T. Bargetzi, M. Barnard, D.L. Bartsch, H.H. Baruchel, A. Battista, C. Bay, J.-O. Bayik, M. Bazarbachi, A. Beguin, Y. López, J.L.B. Benedek, I. Benedetti, F. Bengala, C. Berrebi, A. Besalduch, J. Biesma, D. Biron, P. Björkholm, M. Blaise, D. Blesing, N.E. Boasson, M. Bobev, D. Boccadoro, M. Bolaman, Z. Boogaerts, M.A. Bordessoule, D. Bosi, A. Aida, B.S. Bourhis, J.H. Bourikas, G. Bowen, D.T. Bregni, M. Bries, G. Brinch, L. Brittain, D. Bron, D. Brune, M. Bullorsky, E.O. Bunjes, D. Burdach, S. Burnett, A.K. Buzyn, A. Caballero, D. Cagirgan, S. Cahn, J.-Y. Canepa, C.O. Cao, A. Carella, A.M. Carrera, F.D. Carret, A.-S. Cascinu, S. Castel, V. Caswell, M. Cavanna, L. Cetto, G.L. Chapuis, B. Chasty, R. Chen, Y.-C. Chisesi, T. Chopra, R. Chybicka, A. Clark, R.E. Colombat, P. Colovic, M.D. Constenla-Figueiras, M. Contreras, M. Contu, L. Cordonnier, C. Cornelissen, J.J. Cornish, J. Coser, P. Costa, N. Coze, C. Craddock, C. Crown, J. Culligan, D.J. Danova, M. Darbyshire, P.J. Davies, J.M. de Bock, R. de Pablos Gallego, J.M. De Prijck, B. de Revel, T. De Rossi, G. De Souza, C.A. Deb, G. Degos, L. Demuynck, H. Dervenoulas, I. Di Bartolomeo, P. Di Renzo, N. Diaz, M.A. Diehl, V. Diez-Martin, J.L. Dincer, S. Giorgio, D. Dmoszynska, A. Doelken, G. Peter, P.D. Dulley, F. Easow, J. Ebell, W. Efremidis, A. Ehninger, G. Eichler, H. Eimermacher, H. Enno, A. Errazquin, L. Aguado, J.E. Everaus, H. Fagioli, F. Fanin, R. Fassas, A. Fasth, A. Faulkner, L.B. Fauser, A.A. Feldman, L. Feremans, W. Ferhanoglu, B. Fernández, M.N. Fernández-Ranada, J.M. Ferrant, A. Ferrara, F. Finke, J. Fischer, A. Fischer, J. Fitzsimons, T. Floristan, F. Forjaz de Lacerda, J.M.F. Fossati-Bellani, F. Fosser, V. Franklin, I. Freund, M. Frickhofen, N. Gabbas, A. Gadner, H. Gallamini, A. Galvin, M.C. López, J.G. García-Conde, J. Gaska, T. Gastl, G. Gedikoglu, G. Ghavamzadeh, A. Gianni, A. Gibson, B.E. Gil, J.L. Gilleece, M.H. Gisselbrecht, C. Glass, B. Gmür, J. Göbel, U. Goldman, J.M. Goldstone, A.H. San Miguel, J.D.G. González-López, M.-A. Grafakos, S. Gramatzki, M. Grañena, A. Gratecos, N. Gratwohl, A. Greinix, H.T. Gugliotta, L. Guilhot, F. Guimaraes, J.E. Gülbas, Z. Gulyuz, O. Gurman, G. Gutierrez, M.M. Haas, R. Hamladji, R.-M. Hamon, M.D. Hansen, N.E. Harhalakis, N. Harousseau, J.L. Hartenstein, R. Hartmann, C.O. Hausmaninger, H. Haznedar, R. Heit, W. Hellmann, A. Herrmann, R.P. Hertenstein, B. Hess, U. Hinterberger, W. Ho, A.D. Hoelzer, D. Holowiecki, J. Horst, H.-A. Hossfeld, D.K. Huebsch, L. Hunter, A.E. Iacopino, P. Iannitto, E. Indrák, K. Iriondo, A. Izzi, T. Jackson, G.L. Jacobs, P. Jacobsen, N. Janvier, M. Jebavy, L. Joensuu, H. Joerg, S. Jones, F.G.C. Jouet, J.P. Joyner, M.V. Juliusson, G. Jürgens, H. Kalayoglu-Besisik, S. Kalman, N. Kalmanti, M. Kansoy, S. Kansu, E. Kanz, L. Karianakis, G. Kernéis, Y. Khalifeh, O. Khomenko, V. Kienast, J. Killick, S. Kirchner, H.H. Klingebiel, T. Knauf, W. Koenigsmann, M. Koistinen, P. Koivunen, E. Kolb, H.-J. Kolbe, K. Koller, E. Komarnicki, M. Koscielniak, E. Kovacsovics, T. Kowalczyk, J.R. Koza, V. Kozak, T. Kugler, J. Kuliczkowski, K. Kvaloy, S. Labar, B. Laciura, P. Palacios, J.J.L. Lakota, J. Lambertenghi, D.G. Lange, A. Lanza, F. Isasti, R.L. Lauria, F. Le Moine, F. Leblond, V. Lelli, G. Lenhoff, S. Leon, L.A. Leoncini-Franscini, L. Leone, G. Leoni, P. Levis, A. Leyvraz, S. Liberati, M. Link, H. Linkesch, W. Liso, V. Lisukov, I.A. Littlewood, T. Ljungman, P. Locatelli, F. Losonczy, H. Lotz, J.-P. Ludwig, H. Lukac, J. Lutz, D. Macchia, P. Madrigal, A. Maiolino, A. Majolino, I. Eloy-García, J.M. Malesevic, M. Mandelli, F. Marc, A. Marcus, R. Marianska, B. Markuljak, I. Marsh, J.C.W. Martelli, M.F. Marti Tutusaus, J.M. Martin, S. Martin, M. Martinelli, G. Martínez-Rubio, A.M. Martoni, A. Maschan, A. Maschmeyer, G. Masszi, T. Mazza, P. McCann, S. Meier, C.R. Messina, C. Mettivier, V. Metzner, B. Michallet, M. Michieli, M. Michon, J. Milligan, D.W. Milone, J.H. Giuseppe, G.M. Minigo, H. Mistrik, M. Moicean, A.D. Monfardini, S. Montserrat, E. Moraleda Jimenez, J.M. Morales-Lazaro, A. Morandi, S. Morra, E. Mufti, G.J. Musso, M. Nagler, A. Nalli, G. Naparstek, E. Narni, F. Nenadov-Beck, M. Neubauer, A. Newland, A.C. Niederwieser, D. Niethammer, D. Noens, L.A. Nousiainen, T. Novik, A. Novitzky, N. Occhini, D. Odriozolas, J. Ojanguren, J.M. O’meara, A. Onat, H. Orchard, K. Ortega, J.J. Osieka, R. Ossenkoppele, G.J. Othman, B. Ovali, E. Ozcebe, O.I. Ozerkan, K. Ozturk, A. Papatryfonos, A. Parker, J.E. Pastore, M. Patrone, F. Patton, N. Pejin, D. Peñarrubia, M.J. Equiza, E.P. Peschel, C. Pession, A. Pigaditou, A. Pignon, B. Pihkala, U. Pimentel, P. Pitini, V. Podoltseva, E. Pogliani, E.M. Anna, A.P. Porta, F. Potter, M. Powles, R. Prentice, G.H. Pretnar, J. Ptushkin, V. Quarta, G. Reiter, A. Remes, K. Reykdal, S. Santasusana, J.M.R. Rifón, J. Rio, B. Rizzoli, V. Robak, T. Robinson, A.J. Rodeghiero, F. Rodríguez Fernández, J.M. Rombos, Y. Romeril, K.R. Rosenmayr, A. Rossi, J.F. Rosti, G. Rotoli, B. Rowe, J.M. Russell, N.H. Ryzhak, O. Rzepecki, P. Saglio, G. Salwender, H. Samonigg, H. Santoro, A. Sanz, M.A. Sayer, H.G. Scanni, A. Schaafsma, M.R. Schaefer, U.W. Schanz, U. Schattenberg, A. Schey, S.A.M. Schlimok, G. Schmoll, H.-J. Schots, R. Schouten, H. Schwarer, A.P. Schwerdtfeger, R. Scimè, R. Segel, E. Seger, R. Selleslag, D. Serban, M. Shamaa, S. Shaw, P.J. Siegert, W. Siena, S. Sierra, J. Simonsson, B. Singer, C.R.J. Sirchia, G. Skotnicki, A.B. Slavin, S. Snowden, J. Sotto, J.J. Tanyeli, A. Tedeschi, L. Tidefelt, U. Tissot, J.-D. Tobler, A. Tomas, J.F. Torres, J.P. Torres, G.A. Touraine, J.-L. Trneny, M. Uderzo, C. Unal, E. Unal, A. Undar, L. Urban, C. Van den Berg, H. van Marwijk, K.M. Vellenga, E. Venturini, M. Verdonck, L.F. Veys, P. Vilardell, J. Vinante, O. Visani, G. Vitek, A. Vivancos, P. Volpe, E. Vora, A. Vorlicek, J. Vowels, M. Vujic, D. Wachowiak, J. Wagner, T. Wahlin, A. Walewski, J. Wandt, H. Weissinger, F. Wijermans, P.W. Wiktor-Jedrzejczak, W. Will, A.M. Woell, E. Wörmann, B. Yaniv, I. Yesilipek, M.A. Yilmaz, U. Yong, A. Zachée, P. Zambelli, A. Zander, A.R. Zintl, F. Zoumbos, N.C. The Acute Leukemia Working Party (ALWP) of the European Cooperative Group for Blood Marrow Transplantation (EBMT)

Abstract

Several studies have compared bone marrow (BM) and peripheral blood (PB) as stem cell sources in patients receiving allografts, but the cell doses infused have not been considered, especially for BM. Using the ALWP/EBMT registry, we retrospectively studied 881 adult patients with acute myelocytic leukemia (AML), who received a non-T-depleted allogeneic BM (n = 515) or mobilized PB (n = 366) standard transplant, in first remission (CR1), from an HLA-identical sibling, over a 5-year period from January 1994. The BM cell dose ranged from 0.17 to 29 × 108/kg with a median of 2.7 × 108/kg. The PB cell dose ranged from 0.02 to 77 × 10 8/kg with a median of 9.3 × 108/kg. The median dose for patients receiving BM (2.7 × 108/kg) gave the greatest discrimination. In multivariate analyses, high-dose BM compared to PB was associated with lower transplant-related mortality (RR = 0.61; 95% CI, 0.39-0.98; P = .04), better leukemia-free survival (RR = 0.65; 95% CI, 0.46-0.91; P = .013), and better overall survival (RR = 0.64; 95% CI, 0.44-0. 92; P = .016). The present study in patients with AML receiving allografts in first remission indicates a better outcome with BM as compared to PB, when the dose of BM infused is rich. © 2003 by The American Society of Hematology.

Published
2003

38. Cidofovir for cytomegalovirus infection and disease in allogeneic stem cell transplant recipients. The Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation

Author

Ljungman, P, Deliliers, G L, Platzbecker, U, Matthes-Martin, S, Bacigalupo, A, Einsele, H, Ullmann, J, Musso, M, Trenschel, R, Ribaud, P, Bornhäuser, M, Cesaro, S, Crooks, B, Dekker, A, Gratecos, N, Klingebiel, T, Tagliaferri, E, Ullmann, A J, Wacker, Pierre, and Cordonnier, C

Subjects
Adult, Male, ddc:618, Adolescent, animal diseases, viruses, Cytomegalovirus Infections/drug therapy/etiology/prevention & control, Data Collection, Organophosphonates, virus diseases, Infant, Middle Aged, Organophosphorus Compounds/administration & dosage/standards/toxicity, Transplantation, Homologous/adverse effects, Cytosine/administration & dosage/analogs & derivatives/standards/toxicity, Survival Rate, Treatment Outcome, Antiviral Agents/administration & dosage/standards/toxicity, Child, Preschool, Drug Evaluation, Humans, Hematopoietic Stem Cell Transplantation/adverse effects, Renal Insufficiency/chemically induced/virology, Child, Retrospective Studies
Abstract

A retrospective study was performed to collect information regarding efficacy and toxicity of cidofovir (CDV) in allogeneic stem cell transplant patients. Data were available on 82 patients. The indications for therapy were cytomegalovirus (CMV) disease in 20 patients, primary preemptive therapy in 24 patients, and secondary preemptive therapy in 38 patients. Of the patients, 47 had received previous antiviral therapy with ganciclovir, foscarnet, or both drugs. The dosage of CDV was 1 to 5 mg/kg per week followed by maintenance every other week in some patients. The duration of therapy ranged from 1 to 134 days (median, 22 days). All patients received probenecid and prehydration. Ten of 20 (50%) patients who were treated for CMV disease (9 of 16 with pneumonia) responded to CDV therapy, as did 25 of 38 (66%) patients who had failed or relapsed after previous preemptive therapy and 15 of 24 (62%) patients in whom CDV was used as the primary preemptive therapy. Of the patients, 21 (25.6%) developed renal toxicity that remained after cessation of therapy in 12 patients. Fifteen patients developed other toxicities that were potentially due to CDV or the concomitantly given probenecid. No toxicity was seen in 45 (61.6%) patients. Cidofovir can be considered as second-line therapy in patients with CMV disease failing previous antiviral therapy. However, additional studies are needed before CDV can be recommended for preemptive therapy.

Published
2001

39. Cidofovir for CMV infection and disease in allogeneic stem cell transplant

Author

Ljungman, P, LAMBERTENGHI DELILIERS, P, Platzbacker, U, Matthesmartin, S, Bacigalupo, A, Einsele, H, Ullmann, J, Musso, M, Trenschel, R., Ribaud, P, Bornhauser, M, Cesaro, Simone, Crooks, B., Dekker, A., Gratecos, N., Klingebiel, T., Tagliaferri, E., Ullmann, A., Wacker, P., and Cordonnier, C.

Subjects
cidofovir, infection, hematopoietic stem cell transplantation, hematopoietic stem cell transplantation, cidofovir, infection
Published
2001

40. Cidofovir for treatment of CMV and adenovirus infections in allogeneic stem cell transplant recipients

Author

Ljungman, P, Deliliers, Gl, Ribaud, P, Einsele, H, Ullmann, J, Musso, M, Trenschel, R, Platzbecker, U, Bacigalupo, A, Bosi, A, Cesaro, Simone, Crooks, B, Dekker, A, Gratecos, N, Klingebiel, T, Tagliaferri, E, Wacker, P, and Cordonnier, C.

Subjects
cidofovir, cytomegalovirus infection, hematopoietic stem cell transplant, cytomegalovirus infection, cidofovir, hematopoietic stem cell transplant
Published
1999

41. Is AraC Required In the Treatment of Standard Risk APL? Long Term Results of a Randomized Trial (APL 2000) From the French Belgian Swiss APL Group

Author

Ades, Lionel, primary, Raffoux, Emmanuel, additional, Chevret, Sylvie, additional, de Botton, Stephane, additional, Guerci, Agnes, additional, Pigneux, Arnaud, additional, Vey, Norbert, additional, Lamy, Thierry, additional, Huguet, Françoise, additional, Muller, Beatrice, additional, Maloisel, Franck, additional, Deconinck, Eric, additional, Caillot, Denis, additional, Gratecos, N., additional, Sotto, Jean Jacques, additional, Ferrant, Augustin, additional, Turlure, Pascal, additional, Thomas, Xavier, additional, Chevallier, Patrice, additional, Ifrah, Norbert, additional, Stamatoullas, Aspasia, additional, Chomienne, Christine, additional, Dombret, Hervé, additional, Degos, Laurent, additional, and Fenaux, Pierre, additional

Published
2010
Full Text
View/download PDF

42. Reduced-Intensity Conditioning (RIC) Allogeneic Stem Cell Transplantation (allo-SCT) For Patients Aged ≥60 Years: A Retrospective Analysis Of 629 Patients From The Societe Francaise de Greffe de Moelle et de Therapie Cellulaire (SFGM-TC)

Author

Mohty, M., primary, Blaise, D., additional, Milpied, N., additional, Michallet, M., additional, Vernant, J.P., additional, Fegueux, N., additional, Guilhot, F., additional, Rio, B., additional, Gratecos, N., additional, Cahn, J.Y., additional, Socie, G., additional, Yakoub-Agha, I., additional, Huynh, A., additional, Francois, S., additional, Bay, J.O., additional, Cordonnier, C., additional, Buzyn, A., additional, Contentin, N., additional, Deconinck, E., additional, and Chevallier, P., additional

Published
2010
Full Text
View/download PDF

43. Allogeneic Stem Cell Immunotherapy for Advanced Metastatic Breast Cancer: The Way Forward

Author

Blaise, D., primary, Goncalves, A., additional, Furst, S., additional, Bay, J.O., additional, Faucher, C., additional, Michallet, M., additional, Boiron, J.M., additional, Cahn, J.Y., additional, Gratecos, N., additional, Mohty, M., additional, Chabannon, C., additional, Gravis, G., additional, Esterni, B., additional, Extra, J.M., additional, and Viens, P., additional

Published
2009
Full Text
View/download PDF

45. Syngeneic transplantation in multiple myeloma - a case-matched comparison with autologous and allogeneic transplantation. European Group for Blood and Marrow Transplantation.

Author

Gahrton, G, Svensson, H, Bjorkstrand, B, Apperley, C, Carlson, K, Cavo, M, Ferrant, A, Fouillard, L, Gratecos, N, Gratwohl, A, Guilhot, F, Lambertenghi Deliliers, G, Ljungman, P, Masszi, T, Milligan, DW, Powles, RL, Reiffers, J, Samson, JD, Stoppa, AM, Vernant, JP, Volin, L, Wallvik, J, Gahrton, G, Svensson, H, Bjorkstrand, B, Apperley, C, Carlson, K, Cavo, M, Ferrant, A, Fouillard, L, Gratecos, N, Gratwohl, A, Guilhot, F, Lambertenghi Deliliers, G, Ljungman, P, Masszi, T, Milligan, DW, Powles, RL, Reiffers, J, Samson, JD, Stoppa, AM, Vernant, JP, Volin, L, and Wallvik, J

Published
1999

46. Is ARAC Required in the Treatment of Newly Diagnosed APL? Results of a Randomized Trial (APL 2000).

Author

Ades, L., primary, Raffoux, E., additional, Chevret, S., additional, de Botton, S., additional, Guerci, A., additional, Pigneux, A., additional, Stoppa, A.M., additional, Lamy, T., additional, Rigal-Huguet, F., additional, Vekhoff, A., additional, Pabst, T., additional, Meyer-Monard, S., additional, Maloisel, F., additional, Deconinck, E., additional, Caillot, D., additional, Gratecos, N., additional, Sotto, J.J., additional, Ferrant, A., additional, Turlure, P., additional, Thomas, X., additional, Fegueux, N., additional, Brault, P., additional, Reman, O., additional, Chevallier, P., additional, Travade, P., additional, Leblond, V., additional, Leverger, G., additional, Stamatoullas, A., additional, Pautas, C., additional, Beve, B., additional, Chomienne, C., additional, Dombret, H., additional, Degos, L., additional, and Fenaux, P., additional

Published
2004
Full Text
View/download PDF

47. Thalidomide salvage therapy following allogeneic stem cell transplantation for multiple myeloma: a retrospective study from the Intergroupe Francophone du Myélome (IFM) and the Société Française de Greffe de Moelle et Thérapie Cellulaire (SFGM-TC)

Author

Mohty, M, primary, Attal, M, additional, Marit, G, additional, Bulabois, C E, additional, Garban, F, additional, Gratecos, N, additional, Rio, B, additional, Vernant, J P, additional, Sotto, J J, additional, Cahn, J Y, additional, Blaise, D, additional, Jouet, J P, additional, Facon, T, additional, and Yakoub-Agha, I, additional

Published
2004
Full Text
View/download PDF

48. Total body irradiation-high-dose cytosine arabinoside and melphalan followed by allogeneic bone marrow transplantation from HLA-identical siblings in the treatment of children with acute lymphoblastic leukaemia after relapse while receiving chemotherapy: a Société Française de Greffe de Moelle study.

Author

UCL, Bordigoni, P., Esperou, H, Souillet, G., Pico, J, Michel, Georges-Henry, Lacour, B., Reiffers, J., Sadoun, A., Rohrlich, P, Jouet, J P, Milpied, N., Lutz, P., Plouvier, E, Cornu, Guy, Vannier, J P, Gandemer, V, Rubie, H., Gratecos, N., Leverger, G., Stephan, J L, Boutard, P, Vernant, J P, UCL, Bordigoni, P., Esperou, H, Souillet, G., Pico, J, Michel, Georges-Henry, Lacour, B., Reiffers, J., Sadoun, A., Rohrlich, P, Jouet, J P, Milpied, N., Lutz, P., Plouvier, E, Cornu, Guy, Vannier, J P, Gandemer, V, Rubie, H., Gratecos, N., Leverger, G., Stephan, J L, Boutard, P, and Vernant, J P

Abstract

We investigated the use of a new conditioning regimen followed by allogeneic bone marrow transplantation (BMT) for treating children with acute lymphoblastic leukaemia (ALL) after relapse within 6 months of the completion of therapy. One hundred and sixteen children with acute lymphoblastic leukaemia in second or subsequent complete remission (CR) underwent allogeneic bone marrow transplantation from HLA-identical siblings after a preparative regimen comprising total body irradiation (TBI), high-dose cytosine arabinoside and melphalan (TAM regimen). The Kaplan-Meier product-limit estimate (mean +/- SE) of disease-free survival (DFS) at 7 years was 59.5 +/- 9% (95% confidence interval). The estimated chance of relapse was 22.5 +/- 15% with a median follow-up of 88.5 months (range 51-132). 26 patients (22.4%) died with no evidence of recurrent leukaemia, mainly from interstitial pneumonitis, veno-occlusive disease or acute graft-versus-host disease (GVHD). Three factors significantly affected DFS: acute GVHD. site of relapse and, for children in second remission after a marrow relapse, the disease status at the time of transplantation. The DFS were 59.02 +/- 12.6%, 37.5 +/- 19.8% and 774 +/- 15% among patients in CR2 after a marrow relapse, in CR3 or in untreated partial marrow relapse, and in CR2 after an isolated CNS relapse, respectively. The lowest DFS was seen in children with acute GVHD grades 3-4. Two significant factors were associated with relapse: the marrow status at the time of transplantation and chronic GVHD. The relapse rate was lower among children in CR2 or with chronic GVHD. We conclude that transplantation after the TAM regimen is an effective therapy for this population with acceptable toxicity, particularly for children in second remission after a very early marrow relapse, or those with early isolated CNS involvement.

Published
1998

49. Late effects of allogeneic bone marrow transplantation for children with acute myeloblastic leukemia in first complete remission: the impact of conditioning regimen without total-body irradiation--a report from the Société Française de Greffe de Moelle.

Author

Michel, G, primary, Socié, G, additional, Gebhard, F, additional, Bernaudin, F, additional, Thuret, I, additional, Vannier, J P, additional, Demeocq, F, additional, Leverger, G, additional, Pico, J L, additional, Rubie, H, additional, Mechinaud, F, additional, Reiffers, J, additional, Gratecos, N, additional, Troussard, X, additional, Jouet, J P, additional, Simonin, G, additional, Gluckman, E, additional, and Maraninchi, D, additional

Published
1997
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results